Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
UNSPSC Code:
41115700
NACRES:
SB.52
eCl@ss:
32110501
L × i.d.:
7.5 cm × 2.1 mm
Matrix active group:
C18 (octadecyl) phase
Pore size:
160 Å
Matrix:
Fused-Core particle platform, superficially porous particle
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aidermaterial
stainless steel column
Quality Level
agency
suitable for USP L1
product line
Ascentis®
feature
endcapped: no
packaging
pk of 1 ea
manufacturer/tradename
Ascentis®
parameter
≤100 °C temp. range, 600 bar max. pressure (9000 psi)
technique(s)
HPLC: suitable, LC/MS: suitable, UHPLC-MS: suitable, UHPLC: suitable
L × I.D.
7.5 cm × 2.1 mm
surface area
90 m2/g
impurities
<5 ppm metals
matrix
Fused-Core particle platform, superficially porous particle
matrix active group
C18 (octadecyl) phase
pore size
160 Å
operating pH range
1-9
separation technique
reversed phase
General description
Ascentis Express Peptide ES-C18 columns are specifically engineered to separate higher molecular weight compounds such as peptides and small proteins. These columns contain advanced Fused-Core particles that have larger pores (160 Å versus 90 Å in standard Ascentis Express), bonded with sterically-protected C18 ligands to provide extra stability (ES) at very low pH (< 1) and high temperatures (up to 100ºC). This greatly expands the application range for Ascentis Express columns.
Legal Information
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Meiyun Shi et al.
Journal of separation science, 38(8), 1351-1357 (2015-01-30)
The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr, RKDVY) corresponds to amino acids 32-36 of the 49 amino acid immunomodulatory polypeptide, thymopoietin, whose biological activity is partially reproduced. Thymopentin is widely used in the clinic and represents a promising target for drug design but
E Lesellier
Journal of chromatography. A, 1266, 34-42 (2012-11-03)
The recent introduction of new stationary phases for liquid chromatography based on superficially porous particles, called core-shell or fused-core, dramatically improved the separation performances through very high efficiency, due mainly to reduced eddy diffusion. However, few studies have evaluated the
C Gröer et al.
Journal of pharmaceutical and biomedical analysis, 100, 393-401 (2014-09-15)
Cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGT) are major determinants in the pharmacokinetics of most drugs on the market. To investigate their impact on intestinal and hepatic drug metabolism, we developed and validated quantification methods for nine CYP (CYP1A2, CYP2B6